Share Price
26.00 p
-0.5 (-1.89 %)
Market Cap
£12.16 m
Proactive Investors - Run By Investors For Investors


Scope expanded with top 10 biopharma company

RNS Number : 3018J
04 December 2018

4 December 2018



("IXICO" or the "Company")


IXICO signs expanded scope to current contract with top 10 biopharmaceutical company


Increasing contract value by $2.4m over the remaining term


IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed an expanded scope to a current contract with a top 10 biopharmaceutical company. Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.


The expanded scope will see IXICO providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.


Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted that our client has decided to expand our involvement in this important study. We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO's ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress."


For further information please contact:



Giulio Cerroni, Chief Executive Officer

Susan Lowther, Chief Financial Officer


Tel: +44 20 3763 7499

Shore Capital (Nomad and Broker)

Edward Mansfield/Anita Ghanekar/Daniel Bush


Tel: +44 20 7408 4090

FTI Consulting Limited (Investor Relations)

Simon Conway/Mo Noonan


Tel: +44 20 3727 1000




IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.


IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.


More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

IXICO PLC Timeline

December 11 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use